Adia Med Q3 10-Q: Going Concern Warning Persists Despite Revenue Nearly Doubling
ADIA has more than doubled off its 52-week low of $0.023 on light trading volume (0.2× avg).
Summary
Adia Med's Q3 2026 10-Q shows revenue nearly doubling to $1.02M for nine months, but a $271,922 net loss, a $16.2M accumulated deficit and a reiterated going concern warning, plus disclosure controls deemed not effective.
Key Events · Earnings and Guidance · ADIA
-
Going Concern Doubt Reiterated
Management states the $16,245,404 accumulated deficit and $128,369 working capital raise substantial doubt about continuing as a going concern for a reasonable period.
-
Revenue Nearly Doubles, Loss Persists
Nine-month revenue rose to $1,019,245 from $521,958, but the company posted a $271,922 net loss and used $239,653 of cash in operations.
-
Disclosure Controls Not Effective
The CEO and CFO concluded disclosure controls and procedures were not effective as of September 30, 2026.
-
Q2 2026 Figures Revised Downward
An immaterial error in IRB study revenue recognition cut $96,800 from previously reported revenue and net income for the three and six months ended June 30, 2026.
Analysis · ADIA · Life Sciences
Revenue for the first nine months of 2026 nearly doubled to $1,019,245 from $521,958, yet the company still lost $271,922 and carries a $16,245,404 accumulated deficit with only $128,369 of working capital. Management explicitly states these factors raise substantial doubt about the ability to continue as a going concern, and disclosure controls were concluded not effective. The cash balance of $1,137,818 looks healthier only because of the $1,000,000 cash received from selling 30% of Adia Labs; operations themselves burned $239,653. The company also revised its Q2 2026 figures, cutting $96,800 of previously reported revenue and net income. For a nano-cap trading near $0.13, the going concern language and ineffective controls are the dominant facts.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIA was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $0.02 to $0.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.